THE European Medicines Agency
(EMA) is reviewing medicines
containing hydroxyzine, approved
for uses including anxiety disorders
and as premedication for surgery.
The Hungarian medicines agency
requested the review over concerns
about the side effects of these
medicines on the heart, with
data from pharmacovigilance and
studies found a potential increased
risk of alterations of the heart’s
electrical activity and arrhythmias.
The Therapeutic Goods
Administration said hydroxyzine
was on the Australian Register of
Therapeutic Goods as an export
only medicine, but it was aware
of the review and would keep a
watching brief on its outcomes.The above article was sent to subscribers in Pharmacy Daily's issue from 12 May 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 May 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.